Zacks Research Has Strong Estimate for ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Zacks Research raised their FY2024 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($2.52) for the year, up from their prior estimate of ($2.65). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.26) EPS, Q1 2026 earnings at $0.33 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.64 EPS and FY2026 earnings at $1.71 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the company posted $1.15 EPS. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis.

A number of other equities research analysts have also recently weighed in on ALNY. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Chardan Capital reiterated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Stock Up 2.5 %

Shares of NASDAQ ALNY opened at $250.98 on Monday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business’s 50 day moving average is $273.13 and its two-hundred day moving average is $238.67. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The firm has a market cap of $32.37 billion, a price-to-earnings ratio of -95.79 and a beta of 0.39.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its position in shares of Alnylam Pharmaceuticals by 30.3% during the first quarter. Acadian Asset Management LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 386 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in Alnylam Pharmaceuticals by 9.6% in the first quarter. O Shaughnessy Asset Management LLC now owns 2,181 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 191 shares during the last quarter. UniSuper Management Pty Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the first quarter. UniSuper Management Pty Ltd now owns 1,800 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 900 shares during the period. Natixis acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $102,000. Finally, Advisors Asset Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 194.0% during the first quarter. Advisors Asset Management Inc. now owns 4,037 shares of the biopharmaceutical company’s stock worth $603,000 after acquiring an additional 2,664 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.